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Abstract
Introduction: Studies have shown that transgender women (TGW) are disproportionately affected by HIV, with an estimated HIV
prevalence of 19.1% among TGW worldwide. After receiving a diagnosis, HIV-positive TGW have challenges accessing effective
HIV treatment, as demonstrated by lower rates of virologic suppression and higher HIV-related mortality. These adverse HIV
outcomes have been attributed to the multiple sociocultural and structural barriers that negatively affect their engagement
within the HIV care continuum. Guidelines for feminizing hormonal therapy among TGW recommend combinations of
oestrogens and androgen blockers. Pharmacokinetic studies have shown that certain antiretroviral therapy (ART) agents, such as
protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and cobicistat, interact with ethinyl estradiol,
the key oestrogen component of oral contraceptives (OCPs). The goal of this article is to provide an overview of hormonal
regimens used by TGW, to summarize the known drug-drug interactions (DDIs) between feminizing hormonal regimens and ART,
and to provide clinical care recommendations.
Methods: The authors identified English language articles examining DDIs between oestrogen therapy, androgen blockers and
ART published between 1995 and 2015 using PubMed, Cumulative Index to Nursing and Allied Health Literature and EBSCOhost.
Results and Discussion: Published articles predominantly addressed interactions between ethinyl estradiol and NNRTIs and PIs.
No studies examined interactions between ART and the types and doses of oestrogens found in feminizing regimens. DDIs that
may have the potential to result in loss of virologic suppression included ethinyl estradiol and amprenavir, unboosted
fosamprenavir and stavudine. No clinically significant DDIs were noted with other anti-retroviral agents or androgen blockers
Conclusions: There are insufficient data to address DDIs between ART and feminizing hormone regimens used by TGW. There is
an urgent need for further research in this area, specifically pharmacokinetic studies to study the direction and degree of
interactions between oral, injectable and transdermal estradiol and ART. Clinicians need to be vigilant about possible
interactions and monitor hormone levels if concerns arise. More research is also needed on the provision of hormone therapy
and gender-affirming care on the long-term health outcomes of HIV-positive TGW.
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Introduction
HIV prevalence among transgender women
Transgender individuals are those whose gender identities
and/or gender expression do not fully align with their
assigned sex at birth. Many cultures around the world re-
cognize transgender people using varied terms such as
‘‘Kathoeys’’ in Thailand [1]; ‘‘Hijras’’ in India, Bangladesh
and Pakistan [24]; ‘‘Warias’’ in Indonesia [5]; the ‘‘Rae
Rae’s’’ and ‘‘Mahu’s’’ in French Polynesia [6]; and ‘‘Travestis’’
of Latin America [7]. Currently, there are no national-level
estimates of the prevalence of transgender identity for any
country, although India, Bangladesh, Nepal and Pakistan
have recently added a third gender option to the census.
Approximately 0.5% of adults (aged 1864) who participated
in the Massachusetts Behavioral Risk Factor Surveillance
System self-identified as transgender when a gender identity
question was included in the survey [8]. The lack of inclusion
of gender identity in national census data in most countries
means that the true size of the transgender population is
unknown, confounding public health efforts to fully under-
stand the extent of HIV burden within these populations.
Despite the fact that few countries use HIV surveillance
methods that permit the identification of transgender people,
global estimates have demonstrated an increased HIV burden
among transgender women (TGW), with a pooled HIV pre-
valence of 19.1%, and an odds of HIV among transwomen
48 times that of the general population [9]. Although
limited data exist on HIV incidence, two studies demonstrate
incidence among TGW of 3.4 to 7.8 per 100 person-years,
placing them as the group at highest risk for HIV infection
[10,11].
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TGW and the HIV continuum of care
TGW face a complex array of psychosocial challenges that
complicate their access and adherence to HIV care, such as
limited access to and avoidance of health care because of
stigma and past negative experiences with providers, prior-
itization of gender-related health care and concerns about
adverse interactions between antiretroviral therapy (ART)
medications and hormone therapy [12,13]. Social and eco-
nomic marginalization because of transphobia (negative
societal attitudes towards transgender persons) often result
in poverty and unstable housing, familial alienation, limited
formal education, limited social support, mental illness,
trauma and victimization, substance abuse and introduction
to sex work often at an early age [1420]. These factors can
result in late or no presentation to HIV medical care and poor
health outcomes [21].
Data on the HIV care continuum among TGW are limited
because both informational and institutional erasures render
many TGW invisible in data collection and research [22]. HIV
testing rates reveal that many HIV-positive TGW are less likely
than the general population to be aware of their HIV status
despite their elevated HIV risk [23]. Melendez et al. also
showed disparities with ART at one clinical site, with fewer
TGW (59%) than non-transgender people (82%) taking ART
[24]. Even when receiving ART, TGW have been shown to be
significantly less likely to report optimal adherence [25].
A study examining community viral load in San Francisco
demonstrated that TGW had a higher community viral load,
almost three times compared to non-transgender persons,
consistent with low rates of ART [26]. A study evaluating
the care continuum among newly diagnosed TGW in San
Francisco revealed that 77% reported being linked to primary
care within three months of their HIV diagnosis, 65% were
taking ART, but only 44% were virologically suppressed (viral
load 5200 copies/mL) [27]. This last study likely represents
a ‘‘best-case scenario’’ because many TGW may not be
engaged in care [13], but the indicators still fall short of the
UNAIDS 90-90-90 targets [28].
Hormone therapy for TGW
Hormone therapy is one aspect of gender-affirming care that
is utilized as part of medical transition. Gender affirmation in
clinical settings goes far beyond hormones and includes the
creation of a welcoming environment, including the use of
patients’ preferred names and pronouns and providers who
are knowledgeable about transgender health issues [29]. The
desire for gender-affirming health care, such as hormone
therapy, is a critical factor that may both serve as an adjunct
to and require special considerations for effective engage-
ment in HIV medical care. Anecdotal reports from health care
providers indicate that hormone treatment can be an
incentive for TGW to seek and adhere to ART [30].
The goal of feminizing hormone therapy is to induce
the secondary sex characteristics of the affirmed gender and
to reduce the sex characteristics of the individual’s natal sex.
For TGW, feminizing regimens usually involve the use of
an androgen blocker in addition to oestrogen, with many
regimen options available, as outlined in Table 1. Feminizing
hormonal regimens result in favourable effects, including
breast growth, softening of the skin, slowing of androgenetic
hair loss and fat redistribution, however will not have an
effect on beard hair or voice, for which electrolysis/laser treat-
ment and voice therapy are recommended [31,32].
In the United States, spironolactone, a mineralocorticoid-
receptor antagonist with anti-androgen properties, is most
frequently used for androgen blockade [31]. Cyproterone
acetate and gonadotropin-releasing hormone (GnRH) ago-
nists are the androgen blockers most frequently used in
Europe [33,35]. Oestrogen may be administered by oral,
intramuscular or transdermal routes [31]. The World Profes-
sional Association of Transgender Health recently published
the latest recommendations for the health of transsexual,
transgender and gender non-conforming people, and these
Table 1. Examples of oestrogens, androgen blockers, routes and dosing used in feminizing hormone regimens
Route Dose
Hormone
Estradiol/estradiol valerate Oral or sublingual 28 mg daily
Estradiol valerate Intramuscular 2040 mg every 2 weeks
Estradiol cypionate Intramuscular 2 mg every week or 5 mg every 2 weeks
Estradiol gel Topical Topical 0.75 mg two to three times daily
Estradiol patch transdermal Transdermal 25400 mg
Conjugated equine oestrogens (not recommended  see text) Oral
Ethinyl estradiol (not Recommended  see text) Oral
Anti-androgen
Spironolactone Oral 50400 mg daily
Finasteride Oral 2.55 mg daily
Cyproterone acetate Oral 50150 mg daily
Goreselin Subcutaneous 3.6 mg/month or 11.25 mg/3 months
Leuprolide acetate Intramuscular 3.75 mg/month
Sources: Adapted from Royal College of Psychiatrists [33], Hombre et al. [31] and the Blueprint for the provision of comprehensive care for trans
people and trans communities in Asia and the Pacific [34].
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guidelines are widely used in the USA and internationally
[32]. Several countries have also published their own guide-
lines, to reflect the local availability and acceptability of
hormonal formulations as summarized in Table 2.
Utilization of feminizing hormonal therapy among TGW
The proportion of TGW who opt to start hormones varies
significantly across countries because of the availability
of oestrogens and androgen blockers, cost and whether
these are available only through medical sources or without
prescriptions. In addition, some TGW opt not to use hormones
for personal/identity reasons or medical contraindications.
The highest rates of hormone use are in countries where
hormones are readily available without prescription, and
where a greater level of acceptance exists towards transgen-
der persons, for example, Thailand, where studies report
hormone use among TGW of 73 to 94%, mostly obtained
without a prescription [3840]. In the USA and Canada,
hormone utilization among TGW is reported to be 27 to 93%
[23,4145], with up to 60% obtaining their hormones outside
of the medical system [44,4648]. The lowest rates of non-
prescription hormone use are reported in Canada and the
UK, two countries where hormones are available through the
health care system at no expense to the transgender client
[46,49]. Use of non-prescription hormones is associated with
less knowledge about clinical guidelines and adverse effects
of hormones [49,50]. Users of non-prescription hormones
usually do so because of difficulty accessing gender-affirming
care and are therefore less likely to be monitored appro-
priately and to use optimal regimens [44,50]. Both ethinyl
estradiol (a potent oestrogen and a component of oral
contraceptives, or OCPs) and conjugated equine oestrogens
are no longer recommended as feminizing agents because of
the increased risk of venous thromboembolism [51,52].
Outside of health care settings these agents are often used
by TGW for medical transition [37,50].
Comorbidities and other considerations
Since the advent of ART, people living with HIV are living
longer, healthier lives. There has been an increase in aware-
ness of some of the age-related health conditions that are
more prevalent in this population that hold particular con-
siderations for HIV-positive TGW receiving hormone therapy.
Low bone mineral density (BMD) has been reported to
occur more frequently in HIV-positive individuals [53,54] as
well as HIV-negative individuals receiving tenofovir disoproxil
fumarate (TDF) for pre-exposure prophylaxis (PrEP) [55]. This
is a particular concern for TGW because hormones have a
direct effect on bone metabolism. There is evidence that the
risk of osteopenia and osteoporosis may be elevated in TGW
even before initiation of hormone therapy [56]. Reasons
include reduced engagement in sports resulting in lower
muscle mass and grip strength and lower levels of vitamin D
levels [56]. After starting feminizing regimens there are
inconsistent data about risk for osteopenia, with studies
showing increase, decrease or no change in BMD [5759].
The differences in results may be because of the regimens
used (some used unopposed androgen blockers for a period
of time before initiating hormones) and length of follow-up.
Known risk factors for osteoporosis include underutilization
of hormones after gonadectomy or use of androgen blockers
without or with insufficient oestrogen [31]. GnRH agonists
also may result in short-term decline in BMD [60].
Cardiovascular disease (CVD) is another area of special
concern for TGW living with HIV. A recent prospective study
demonstrated increased CVD mortality in this population
[61]. Feminizing hormone therapy may be an independent
risk factor for CVD; however, this population also experiences
higher rates of other CVD risk factors including tobacco use,
obesity, diabetes and dyslipidemias [6167]. The already
well-documented high rates of CVD among people living with
HIV make this an additional concern for HIV-positive TGW
receiving hormones. In the absence of clinical trials evaluat-
ing health outcomes associated with different hormone
regimens, clinicians have advocated the use of transdermal
oestrogens in those with a history of CVD or a predominance
of risk factors, based on studies conducted in postmenopau-
sal women [68,69].
Table 2. Selected international guidelines for transgender health care
Agency Year Guideline
The Endocrine Society, USA [31] 2009 Endocrine treatment of transsexual persons: an Endocrine Society clinical
practice guideline
The World Professional Association of Transgender Health
(WPATH) [32]
2011 Standards of care for the health of transsexual, transgender, and gender-
nonconforming people, Version 7
Counties Manukau District Health Board, Wellington,
New Zealand [36]
2011 Gender reassignment health services for trans people within New Zealand.
good practice guide for health professionals
Royal College of Psychiatrists, London, UK [33] 2013 Good practice guidelines for the assessment and treatment of adults with
gender dysphoria, 2013
Pan American Health Organization [37] 2014 Blueprint for the provision of comprehensive care for trans persons and their
communities in the Caribbean and other Anglophone countries
Health Policy Project, Asia Pacific Transgender Network,
United Nations Development Programme [34]
2015 Blueprint for the provision of comprehensive care for trans people and trans
communities in Asia and the Pacific
Center of Excellence for Transgender Health, University of
California, San Francisco
2016 Guidelines for the primary care of transgender, gender nonconforming, and
gender non-binary people
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Guidelines for ART
The goals of HIV treatment are to improve health outcomes
for people living with HIV and to reduce HIV transmission.
There are five classes of antiretroviral agents that have
different mechanisms of action during the HIV life cycle.
Effective treatment regimens usually consist of ART with at
least three agents. The initial regimen usually includes three
agents from two classes, most often two nucleoside reverse
transcriptase inhibitors (NRTIs) with either a non-nucleoside
reverse transcriptase inhibitor (NNRTI), a protease inhibitor
(PI), which is usually ‘‘boosted’’ with ritonavir, or an integrase
strand transfer inhibitor (INSTI). Two other antiretroviral
agents block entry of HIV into human cells using different
mechanisms, the CCR5 receptor antagonists and fusion
inhibitors.
The recent update in WHO HIV treatment guidelines,
expanding ART to all individuals regardless of CD4 cell count,
means that an additional 9 million individuals, including
many transgender individuals, are now eligible for ART. It is
extremely timely therefore to determine what impact, if any,
hormone therapy has on the uptake as well as adverse effect
profile of ART.
The recommendations for initial antiretroviral regimens
vary globally based on considerations such as cost, avail-
ability of generic agents, adverse effect profile and preva-
lence of comorbidities. The WHO guidelines recommend an
initial regimen of two NRTIs, either lamivudine (3TC) or
emtricitabine (FTC) with TDF and the NNRTI efavirenz (EFV),
or if not available, nevirapine (NVP) [70]. Other NRTI options
to use in place of tenofovir include zidovudine (ZDV) [70]. In
the USA, the two guidelines predominantly used are the
International Antiviral Society-USA Panel and Department of
Health and Human Services (DHHS) Panel on Antiretroviral
Guidelines for Adults and Adolescents [71,72]. Both guide-
lines recommend the use of INSTIs, such as dolutegravir or
elvitegravir in initial regimens, as well as the PI darunavir, in
combination with two NRTIs (TDF, FTC or 3TC); however,
minor differences exist in the recommendations for other
agents.
TGW and PrEP
The use of emtricitabine and TDF for PrEP is an important
biomedical intervention in preventing HIV acquisition. A
recent substudy of the iPrEx trial revealed that TGW were
less likely to have detectable drug levels compared to non-
transgender MSM [30]. Furthermore, TGW may have con-
cerns about potential interactions between feminizing
hormone regimens and PrEP that reduce the likelihood of
PrEP uptake among HIV-negative TGW [25].
Potential interactions between antiretroviral regimens and
feminizing hormone regimens
The current guidelines for transgender care listed in Table 2
do not address interactions between ART and hormonal
therapy; however, potential interactions may exist.
Many antiretroviral agents are metabolized through the
cytochrome P450 (CYP) system [72], allowing for potential
drug-drug interactions (DDIs) with other medications that
use the same pathway and often resulting in unpredictable
changes. Most of the studies that examine for interac-
tions between antiretrovirals and oestrogens have focused
primarily on OCPs, because the predominant concern has
been effects on the efficacy of contraception in HIV-positive
non-TGW. Ethinyl estradiol, the main component of OCPs, is
predominantly metabolized through the cytochrome P450
3A4 (CYP3A4) enzyme pathway, presenting concerns for
interactions with the NNRTIs efavirenz and nevirapine, which
are CYP3A4 inducers, and the PIs, which are metabolized by
and known to be potent CYP3A4 inhibitors [73]. Under-
standing the potential for interactions is important because
untoward increases in oestrogen or antiretroviral drug levels
may cause serious adverse effects, whereas those that
reduce these drug levels may result in loss of virologic sup-
pression or inadequate feminization. In qualitative studies,
TGW have reported fears that ART can limit the effect of
hormones, a serious concern for this population [12]. Faced
with this dilemma, TGW have reported that they may
prioritize gender-affirming health care over HIV treatment
[12] which underscores the importance of having evidence-
based data on DDIs.
Methods
To identify studies investigating antiretroviral agents and the
components of feminizing hormone regimens, the authors
retrieved English language articles from 1995 to 2015 using
PubMed (MEDLINE), Cumulative Index to Nursing and Allied
Health Literature (CINAHL) and EBSCOhost. Medical subject
headings (MeSH) terms for ART (‘‘Antiretroviral,’’ ‘‘HAART,’’
‘‘Anti-HIV Agents’’) were cross-referenced with feminizing
hormonal agents (including ‘‘estrogen,’’ ‘‘estradiol,’’ ‘‘hormonal
contraceptives’’) and androgen blockers (‘‘spironolactone,’’
‘‘finasteride,’’ ‘‘gonadotropin releasing hormone agonist,’’
‘‘GnRH,’’ ‘‘leuprolide,’’ ‘‘goreselin’’). Androgen blockers were
also cross-referenced with ‘‘interactions.’’ The authors re-
viewed abstracts for relevance, with subsequent full-text
review for data abstraction. Inclusion criteria were primary
DDI and pharmacokinetic studies that evaluated interactions
between antiretroviral agents and oestrogens or androgen
blockers. Additional information was obtained from pharma-
cokinetic data listed in package inserts for antiretroviral agents
and named anti-androgens, the University of Liverpool’s HIV
drug interactions website [74] and the DHHS guidelines for
the use of antiretroviral agents in HIV-1-infected adults and
adolescents [72].
Results and discussion
Feminizing hormones
The authors reviewed 165 unduplicated articles that included
references to feminizing hormonal agents. These were re-
viewed for relevance, resulting in identification of 26 peer-
reviewed articles, of which 8 were reviews [73,7581]. Of the
remaining 17 articles, one involved an ART agent no longer in
use [82] and one was for an investigational drug [83]. The
remaining 16 articles were used in this review [8499]. All
but one (an in vitro study) [99] were in vivo pharmacokinetic
DDI studies. All of the available studies evaluated ART inter-
actions with OCPs and not with other feminizing hormones.
The studies were all conducted in non-TGW, with 10 to
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34 participants. In all but five studies [87,88,95,96,98], the
participants were all HIV-negative.
There are few studies that have examined interactions
between exogenous oestrogens and ART, and these have all
investigated effects of OCPs [76]. Although we can speculate
about the direction of interactions based on these data, they
may not reflect the true interactions seen using the types
and doses of oestrogens used in feminizing regimens. One
review found that many studies of PIs and NNRTIs showed
inconsistencies in the direction and level of interactions, mainly
because of differences in study design and OCP regimen [76].
Table 3 summarizes all known effects of ART on ethinyl
estradiol. The only known interactions of ethinyl estradiol on
ART that have the potential to result in loss of virologic
suppression are with amprenavir, unboosted fosamprenavir
and stavudine [72,99], although the latter was a single in vitro
study in peripheral blood lymphocytes. It may be prudent
however to recommend that these ART drugs be avoided in
the treatment of TGW receiving feminizing hormones.
Anti-androgens
There were no published pharmacokinetic studies that
investigated interactions between ART and spironolactone
or finasteride. Drug package inserts, the DHHS guidelines and
the HIV drug interactions website also did not flag potential
drug interactions with these agents. Finasteride is an in-
hibitor of type II alpha-reductase, blocking conversion of
testosterone to 5-alpha-dihydrotestosterone (DHT). Although
finasteride is primarily metabolized through the CYP3A4, it
has no effects on the cytochrome P450 system [100,101];
therefore, it is unlikely to have an effect on ART levels.
When finasteride is co-administered with etravirine, efavirenz
or nevirapine, this may result in decreased finasteride
levels, but the clinical significance of this is unknown [74].
Spironolactone, the agent most often used in feminizing regi-
mens in the USA, is also metabolized through the cytochrome
P450; however, no relevant DDIs occur with ART through this
mechanism [74]. The GnRH agonists leuprolide and goreselin
are both metabolized through intravascular and extravascular
hydrolysis of the C-terminal amino acids followed by excre-
tion in the urine [102,103]. No pharmacokinetic-based DDI
studies have been conducted with these agents [102,103].
A special consideration for HIV-positive TGW is that anti-
androgens may be unnecessary for medical transition purposes
because HIV infection is frequently associated with low tes-
tosterone levels. Studies of HIV-positive natal men have shown
a prevalence of hypogonadism of approximately 25% [104].
Before the initiation of hormonal therapy, total testosterone
levels should be checked.
This review did not find evidence of clinically significant
interactions between ART and feminizing hormones (ethinyl
estradiol) for medical transition. Although the possible in-
crease in CVD and osteoporosis among TGW living with HIV is
concerning, it underscores the importance of engagement in
HIV primary care, which as noted above could be enhanced
by provision of hormone therapy and other gender-affirming
services. Engagement in primary care services will allow for
appropriate health care screenings as well as identification
and reduction of modifiable cardiovascular risk factors, such
as tobacco use, hyperlipidemia, overweight and obesity.
In fact, bundling HIV care with hormone and other aspects
of gender-affirming care may result in synergistic enhance-
ments, as has been demonstrated in other medical contexts.
A preliminary data analysis, led by MD, of the ongoing HRSA
SPNS Transgender Women of Color initiative found associa-
tions between current ARV use, undetectable viral load and
receipt of HIV primary care in the past six months and
receiving a hormone prescription from the participant’s HIV
primary care provider (as opposed to other sources).
Conclusions
Although the data investigating oestrogens and ART come
mainly from OCP data, it is likely that, apart from amprenavir,
unboosted fosamprenavir and possibly stavudine, no clinically
significant interactions exist between feminizing regimens
and ART. These data are also important for HIV prevention
among at-risk HIV-negative TGW, who may not be inclined
to use PrEP until clear information is available about
potential interactions between TDF and feminizing hormone
regimens [105].
Clinicians should maintain vigilance for perceived or actual
interactions between hormone therapy and ART, and
take appropriate clinical or patient educational action as
Table 3. Interactions between antiretroviral therapy and
ethinylestradiol
Effect on ethinyl
estradiol levels
(AUC) Antiretroviral Change
Increase Atazanavir [72]
Etravirine [89]
Fosamprenavir [72]
Rilpivirine [72,90]
AUC  48%
AUC  22%
Cmin  32%
AUC  014%,Cmax17%
Decrease Atazanavir/ritonavir
[72,84]
Darunavir/ritonavir [86]
Fosamprenavir/
ritonavir [84]
Lopinavir/ritonavir
[72,87]
Nevirapine [72,88]
EVG/c/TDF/FTC [72]
Tipranavir/ritonavir [72]
AUC ¡ 19%, Cmax ¡ 16%
and Cmin ¡ 37%
AUC ¡ 44%, Cmin ¡ 62%,
Cmax ¡ 32%
AUC ¡ 37%, 28% ¡ Cmax
and 34%
AUC ¡ 42%, Cmax ¡
41%¡58%
AUC ¡ 29%
AUC ¡ 25%, Cmin ¡ 44%
AUC ¡ 37 to 48%
No effect Dolutegravir [72,97]
Efavirenz [94]
Maraviroc [91]
Raltegravir [72,92]
Tenofovir [94]
Zidovudine [95]
No data Abacavir
Atazanavir/cobicistat
Darunavir/cobicistat
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indicated. This may include monitoring estradiol levels while
on ART in order to assess for elevated or subtherapeutic
levels as well as ongoing viral load monitoring.
Clinicians should be aware of the possible increase in CVD
and osteoporosis among HIV-positive TGW on hormones and
seek to identify and reduce modifiable risk factors.
There is an urgent need for further research, specifically
pharmacokinetic and pharmacodynamics studies to evaluate
for interactions between oral, injectable and transdermal
estradiol and ARTs. More research is also needed on the
impact of hormone therapy on long-term health outcomes of
HIV-positive TGW, not only to evaluate adverse effects but
also to assess the potential positive impact of hormones on
HIV-specific outcomes, like retention and engagement in care
and virologic suppression as well as other preventive health
needs.
The key limitation to this review is the lack of evidence-
based data to support recommendations for TGW living with
HIV. Meaningful inclusion of sexual orientation and gender
identity data in national surveillance systems, as well as
prospective studies investigating the long-term health out-
comes for transgender people accessing medical transition
services, will allow for more robust data upon which to build
guidelines for care.
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